INNOVENT BIO (01801.HK): Seven Innovative Products Join 2026 National Reimbursement List

On 15 Nov 2026, INNOVENT BIO (01801.HK) said seven products joined China's 2026 reimbursement list, four for the first time, taking its total to 17.

NewTimeSpace News: On 15 November 2026, Innovent Biologics, Inc. (stock code: 1801) published a voluntary announcement that seven of its innovative products have been added to the 2026 edition of the National Reimbursement Drug List, which takes effect on 1 January 2027.

Four products were included for the first time: mazdutide injection, a GCG/GLP-1 dual receptor agonist for adults with type 2 diabetes; picankibart injection, an IL-23p19 inhibitor for moderate-to-severe plaque psoriasis; ipilimumab N01 injection, a CTLA-4 inhibitor; and quizartinib hydrochloride tablets, a type II FLT3 inhibitor for newly diagnosed FLT3-ITD mutated acute myeloid leukaemia. Ipilimumab N01 is used with sintilimab as neoadjuvant therapy for resectable stage IIB-III microsatellite instability-high or mismatch repair deficient colon cancer.

Sintilimab injection had two new indications added: with ipilimumab N01 for the same colon cancer neoadjuvant setting, and with fruquintinib for locally advanced or metastatic renal cell carcinoma after failure of a VEGFR-TKI and without prior PD-1 or PD-L1 therapy on first line. Pirtobrutinib tablets, a non-covalent BTK inhibitor, added an indication for chronic lymphocytic leukaemia or small lymphocytic lymphoma, while tafolecimab injection, a fully human PCSK9 monoclonal antibody, was renewed.

The additions span oncology, including colon, kidney and blood cancers, as well as cardiovascular and metabolic disease and autoimmune conditions, bringing the Company's reimbursed innovative portfolio to 17 products and the cumulative number of patients reached to more than 20 million.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.